CPSAR23078 / Kazi / ARST2032
Basic Study Information
Purpose:
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body.
This phase III trial aims to maintain excellent outcomes in patients with very low
risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment
with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized
molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of
the study it to find out how well patients with low risk rhabdomyosarcoma (LR-RMS)
respond to standard chemotherapy when patients with VLR-RMS and patients who have
rhabdomyosarcoma with DNA mutations get separate treatment. Finally, this study examines
the effect of therapy intensification in patients who have RMS cancer with DNA mutations
to see if their outcomes can be improved.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Rafi Kazi
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search